Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Therapy
Patient use of tamoxifen for secondary chemoprevention does not correlate with benefits
December 29th, 2005
Patient use of tamoxifen for secondary chemoprevention does not correlate with the benefits this treatment could provide. According to researchers in the United States, "The purpose of this study was to determine how often patients with ductal carcinoma in situ and T1a/b N0 cancer are offered and accept tamoxifen for secondary chemoprevention. A retrospective review of 284 patients with T1a/b N0 invasive cancer treated between February 1995 and December 2001 and 129 patients with DCIS treated after September 1998 was carried out. Patient and tumor characteristics associated with being offered and accepting tamoxifen were compared." "Tamoxifen was...
Source: Women's Health Weekly (2005-12-29)
|
